Literature DB >> 2738660

Myocardial perfusion imaging with technetium-99m SQ30217: comparison with thallium-201 and coronary anatomy.

D W Seldin1, L L Johnson, D K Blood, M J Muschel, K F Smith, R M Wall, P J Cannon.   

Abstract

Myocardial perfusion in ten normal volunteers and 20 patients with coronary artery disease documented by recent coronary arteriography was studied with 99mTc-labeled SQ30217 and 201TI. Plantar 201TI imaging followed standard treadmill exercise and planar SQ30217 imaging followed upright bicycle exercise, performed to angina, or the same double product achieved on the treadmill test. Upright anterior, 30 degrees left anterior oblique, and 60 degrees left anterior oblique images were obtained for 3, 6, and 9 min, respectively, starting 2 min after injection of 15 mCi of 99mTc SQ30217. A second 15-mCi dose was injected at rest approximately 2 hr later, and the same imaging protocol was followed. No adverse reactions or laboratory abnormalities attributable to SQ30217 were observed. All scans on the normal volunteers were interpreted as normal. Qualitative readings of both tests were equally sensitive for detecting patients with coronary disease (SQ30217 - 16/20, TI - 17/20, p = NS) and identifying abnormal vessels (SQ30217 - 19/45, TI - 21/45, p = NS). Both agents were falsely positive in 1/15 vessels. Ten vascular regions showed persistent abnormalities on resting SQ30217 scans; eight of these were distal to stenoses of at least 90% and three were also abnormal on thallium redistribution images. Hepatic uptake of SQ30217 obscured inferoapical segments in some views in 14/20 patients but did not interfere with abnormal vessel identification.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2738660

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  27 in total

1.  Simultaneous assessment of cardiac perfusion and function using 5-dimensional imaging with Tc-99m teboroxime.

Authors:  Bing Feng; P Hendrik Pretorius; Troy H Farncombe; Seth T Dahlberg; Manoj V Narayanan; Miles N Wernick; Anna M Celler; Jeffrey A Leppo; Michael A King
Journal:  J Nucl Cardiol       Date:  2006 May-Jun       Impact factor: 5.952

2.  Comparison of thallium-201 and technetium-99m teboroxime myocardial single photon emission tomography with coronary arteriography.

Authors:  M Oshima; M Ishihara; H Sano; S Ohsugi; M Ohno; S Hayase; M Yokota; H Akanabe; K Ito; S Sakuma
Journal:  Eur J Nucl Med       Date:  1992

3.  Assessment of myocardial perfusion with Tc-99m: image is everything.

Authors:  Seth T Dahlberg
Journal:  J Nucl Cardiol       Date:  2009-04-30       Impact factor: 5.952

Review 4.  Radiopharmaceuticals: state of the art.

Authors:  A M Verbruggen
Journal:  Eur J Nucl Med       Date:  1990

5.  Novel 99mTc(III)-azide complexes [99mTc(N3)(CDO)(CDOH)2B-R] (CDOH2=cyclohexanedione dioxime) as potential radiotracers for heart imaging.

Authors:  Min Liu; Yumin Zheng; Ugur Avcibasi; Shuang Liu
Journal:  Nucl Med Biol       Date:  2016-05-09       Impact factor: 2.408

6.  Single-photon-emission computed tomography of myocardial perfusion and the hepatic blood pool.

Authors:  D H Lewis; W B Nelp
Journal:  West J Med       Date:  1990-06

7.  Assessment of reperfusion after acute myocardial infarction: is there a role for acute technetium 99m-teboroxime imaging?

Authors:  A J Sinusas
Journal:  J Nucl Cardiol       Date:  1996 Jan-Feb       Impact factor: 5.952

8.  The birth of a new radiopharmaceutical. Clinical investigative perspective.

Authors:  F J Wackers
Journal:  J Nucl Cardiol       Date:  1995 Jan-Feb       Impact factor: 5.952

Review 9.  The maze of myocardial perfusion imaging protocols in 1994.

Authors:  F J Wackers
Journal:  J Nucl Cardiol       Date:  1994 Mar-Apr       Impact factor: 5.952

10.  Preliminary evaluation in humans of Tc-99m-Q3, a new tracer for myocardial perfusion imaging.

Authors:  G Bisi; R Sciagrà; L Bacciottini; D Antoniucci; G M Santoro; P Buonamici; C Bonino
Journal:  Int J Card Imaging       Date:  1993-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.